Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023:2695:127-143.
doi: 10.1007/978-1-0716-3346-5_9.

Diagnosis, Monitoring, and Prognosis of Liquid Biopsy in Cancer Immunotherapy

Weiying Kong  1 , Tengxiang Chen  2 , Yixin Li  3
Affiliations
Review

Diagnosis, Monitoring, and Prognosis of Liquid Biopsy in Cancer Immunotherapy

Weiying Kong et al. Methods Mol Biol. 2023.

Abstract

Liquid biopsy (LB), as a minimally invasive method of gleaning insight into the dynamics of diseases through a patient fluid sample, represents an interesting tool that can advise in disease monitoring, treatment selection, early diagnosis, evaluation of the response, and prognosis. Cancer immunotherapy is a breakthrough in cancer treatment, which is now recognized as the "fourth pillar" of cancer treatment, after surgery, chemotherapy, and radiotherapy. Liquid biopsy offers a different befalling for beneath invasive diagnosis, real-time accommodating monitoring, and analysis options, involving the isolation of circulating biomarkers, such as cell-free DNA (cfDNA), circulating tumor cells (CTCs), exosomes, and microRNAs (miRNAs). The biomarkers herein have great potential to allow the realization of liquid biopsy for predicting the immunotherapy response and precision medicine. Liquid biopsy offers an alternative, less invasive approach to select cancer patients who would benefit from immunotherapy and to monitor patients during their disease course. This review focuses on the use of liquid biopsy in the immunotherapy treatment of patients with cancer. In this review, we addressed the different promising liquid biopsy-based biomarkers in cancer patients that enable the selection of patients who benefit from immunotherapy and the monitoring of patients during this therapy.

Keywords: Biomarkers; Cell-free DNA; Circulating nucleic acids; Circulating tumor cells; Exosomes; Immunotherapy; Liquid biopsy; MicroRNAs.

PubMed Disclaimer

References

    1. Ferlay J et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359–E386 - PubMed - DOI
    1. Fitzmaurice C et al (2019) Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study. JAMA Oncol 5(12):1749–1768 - PubMed - PMC - DOI
    1. KamjDska P et al (2021) Liquid biopsy in melanoma: significance in diagnostics, prediction and treatment monitoring. Int J Mol Sci 22(18):9714
    1. Ricke J, Mohnike K (2021) Radiological interventions in the age of immunotherapy, molecular diagnostics, and liquid biopsy. Manual on image-guided brachytherapy of inner organs: technique, indications and evidence. Mohnike K, Ricke J, Corradini S. Cham, Springer International Publishing, 235–241
    1. Sun R et al (2017) Between-region genetic divergence reflects the mode and tempo of tumor evolution. Nat Genet 49(7):1015–1024 - PubMed - PMC - DOI

LinkOut - more resources